1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of monotherapy ontuxizumab (MORAb-004) plus best supportive care in patients with chemorefractory metastatic colorectal cancer
    Journal Article

    Grothey, A.; Strosberg, J. R.; Renfro, L. A.; Hurwitz, H. I.; Marshall, J. L.; Safran, H.; Guarino, M. J.; Kim, G. P.; Hecht, J. R.; Weil, S. C.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Intravenous mannitol versus placebo during partial nephrectomy in patients with normal kidney function: A double-blind, clinically-integrated, randomized trial
    Journal Article

    Spaliviero, M.; Power, N. E.; Murray, K. S.; Sjoberg, D. D.; Benfante, N. E.; Bernstein, M. L.; Wren, J.; Russo, P.; Coleman, J. A.
    European Urology (2018)

    Fulltext@MSK | Save
  • Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: Subgroup analyses and updated overall survival results
    Journal Article

    Motzer, R. J.; Ravaud, A.; Patard, J. J.; Pandha, H. S.; George, D. J.; Patel, A.; Chang, Y. H.; Escudier, B.; Donskov, F.; Magheli, A.; more...
    European Urology (2018)

    Fulltext@MSK | Save
  • Bayesian nonparametric clustering of patients with advanced cancer on anxiety and depression
    Conference Paper

    Li, Y.; Rosenfeld, B.; Pessin, H.; Breitbart, W.
    IEEE (2017)

    Fulltext@MSK | Save
  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Coleman, R. L.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A.; Scambia, G.; more...
    Lancet (2017)

    Fulltext@MSK | Save
  • Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer
    Journal Article

    Dockery, L. E.; Tew, W. P.; Ding, K.; Moore, K. N.
    Gynecologic Oncology (2017)

    Fulltext@MSK | Save
  • CheckMate 025 randomized phase 3 study: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma
    Journal Article

    Escudier, B.; Sharma, P.; McDermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, G.; Plimack, E. R.; more...
    European Urology (2017)

    Fulltext@MSK | Save
  • RESILIENCE: Phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer
    Journal Article

    Baselga, J.; Zamagni, C.; Gómez, P.; Bermejo, B.; Nagai, S. E.; Melichar, B.; Chan, A.; Mángel, L.; Bergh, J.; Costa, F.; more...
    Clinical Breast Cancer (2017)

    Fulltext@MSK | Save
  • Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: Rationale and design of the CASSINI trial
    Journal Article

    Khorana, A. A.; Vadhan-Raj, S.; Kuderer, N. M.; Wun, T.; Liebman, H.; Soff, G.; Belani, C.; O'Reilly, E. M.; McBane, R.; Eikelboom, J.; more...
    Thrombosis and Haemostasis (2017)

    Fulltext@MSK | Save
  • Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Haas, N. B.; Donskov, F.; Gross-Goupil, M.; Varlamov, S.; Kopyltsov, E.; Lee, J. L.; Melichar, B.; Rini, B. I.; Choueiri, T. K.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save